This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cinqaero
  • /
  • A Study to Evaluate the Efficacy and Safety of Res...
Clinical trial

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma.

Read time: 2 mins
Last updated:1st Apr 2011
Identifier: NCT01287039

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Enrollment: 489
Study Start Date: April 2011
Study Completion Date: March 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)

Arms:
- Placebo Comparator:
Placebo
- Experimental: Reslizumab 3.0 mg/kg


Related journal: Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.

Category Value
Date last updated at source 2016-05-26
Study type(s) Interventional
Expected enrolment 489
Study start date 2011-04-01
Estimated primary completion date 2014-03-01

View full details